405165-61-9
| Name | Besifloxacin hydrochloride |
| CAS | 405165-61-9 |
| EINECS(EC#) | 696-612-6 |
| Molecular Formula | C19H21ClFN3O3.ClH |
| MDL Number | MFCD14636632 |
| Molecular Weight | 430.305 |
| MOL File | 405165-61-9.mol |
Synonyms
Unii-7506A6J57t
Besifloxacin HCl
Hydrochloric Besifloxacin
7-[(3R)-3-AMinohexahydro-
Becifloxacin Hydrochloride
Besifloxacin hydrochloride
Besifloxacin HCl (Besivance)
BESIFLOXACIN HCL INTERMEDIATES
Besifloxacin hydrochloride, >=98%
(R)-7-(3-aMinoazepan-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
(R)-7-(3-AMinohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinolin-3-carboxylic acid HCl
(R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride
7-[(3R)-3-AMinohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid Hydrochloride
3-Quinolinecarboxylic acid, 7-[(3R)-3-aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, hydrochloride (1:1)
3-Quinolinecarboxylic acid, 7-[(3R)-3-aMinohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI)
Chemical Properties
| Melting point | >210°C (dec.) |
| storage temp. | Refrigerator |
| solubility | Methanol (Slightly, Heated, Sonicated), Water (Slightly, Heated, Sonicated) |
| form | Solid |
| color | Off-White to Light Beige |
Hazard Information
Chemical Properties
Pale Yellow Solid
Uses
A Fluoroquinolone antibiotic.
Uses
Besifloxacin HCl is a fourth-generation fluoroquinolone antibiotic
Description
Besifloxacin is a new fluoroquinolone antibacterial for ophthalmic
use. It is indicated for the treatment of bacterial conjunctivitis, one of
the most common ocular infections encountered in the primary care
setting. Although the previously marketed fluoroquinolones ciprofloxacin, levofloxacin, ofloxacin, gatifloxacin, and moxifloxacin have been
widely used to treat bacterial conjunctivitis, their continued utility is
hampered by the emergence of resistance among key ocular isolates
such as Staphylococcus aureus. Besifloxacin is the first
fluoroquinolone developed exclusively for topical ophthalmic use.
Unlike the previously marketed fluoroquinolones, besifloxacin has not
been used systemically and is not in development as a systemic agent. Its
exclusive indication as a topical agent is expected to reduce the overall
environmental exposure of bacteria to besifloxacin, which may contribute to a lower risk for the emergence of bacterial resistance. Fluoroquinolones derive their antibacterial activity via inhibition of two essential
bacterial enzymes, DNA gyrase and topoisomerase IV, which regulate
processes of DNA replication. Besifloxacin inhibits DNA gyrase and topoisomerase IV from Streptococcus pneumoniae (IC50 = 1 and 0.4 mg/ L, respectively) and Escherichia coli (IC50 = 1 and 10 mg/L, respectively).
Originator
SSP Co. Ltd. (Japan) (Japan)
Brand name
Besivance
Side effects
The most common adverse event reported in patients treated with besifloxacin ophthalmic suspension was conjunctival redness. Other less common adverse events were blurred vision, eye pain, eye irritation, eye pruritus, and headache.
Synthesis
Besifloxacin is a fourth-generation fluoroquinolone antibiotic
which is marketed as besifloxacin hydrochloride. It was originally
developed by the Japanese firm SSP Co. Ltd and designated
SS734. SSP then licensed U.S. and European rights of SS734 for ophthalmic
use to InSite Vision, Inc., in 2000, who then developed an
eye drop formulation (ISV-403) and conducted preliminary clinical
trials before selling the product and all rights to Bausch & Lomb in
2003. The eye drop was approved by the United States Food and
Drug Administration (FDA) on May 29, 2009 and marketed under
the trade name Besivance. Besifloxacin has been found to inhibit
production of pro-inflammatory cytokines in vitro. The synthesis of
besifloxacin commences with commercially available ethyl
3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate.Condensation of this ketoester with triethyl orthoformate
resulted in a mixture of vinylogous esters 14. Substitution with
cyclopropanamine converts 14 to the vinylogous amide 15 as an
unreported distribution of cis- and trans-isomers. This mixture
was treated with base at elevated temperature to give 16.
Presumably, the trans-isomer isomerizes to the cis-isomer, which
subsequently undergoes an intramolecular nucleophilic aromatic
substitution with concomitant saponification to construct
quinolone acid 16. Quinolone 16 is then subjected to another
nucleophilic substitution involving readily available iminoazepine
17 and the displacement reaction proceeds regioselectively to furnish
the atomic framework of besifloxacin (18). Acidic methanolysis
of 18 at elevated temperature gave besiflozacin (III).
Questions And Answer
-
Outline
Besifloxacin hydrochloride is developed by Bausch & Lomba as a new type of fluoroquinolones for the treatment of bacterial conjunctivitis (a non-viral caused infectious purulent eye irritation conjunctivitis ). Bacterial conjunctivitis which is a contagious eye disease, is a common disease that affects people of all ages. The clinical symptoms of infested eye including: foreign body sensation, burning sensation, tearing; conjunctival hyperemia, mucus or purulent discharge; eyelid edema, conjunctival edema and subconjunctival hemorrhage may occur in severe cases . ; -
Besifloxacin hydrochloride ophthalmic suspension
Besifloxacin hydrochloride ophthalmic suspension (Besivance) is a fluoroquinolone drug recently approved for the topical treatment of bacterial conjunctivitis. This medicine can quickly kill common pathogens causing conjunctivitis , that is coagulase-negative staphylococci, Streptococcus pneumoniae, Staphylococcus aureus , Haemophilus influenzae bacteria, and other less common bacteria.. Besifloxacin is an effective drug to the Gram-positive and Gram-negative pathogens, include other fluoroquinolone-resistant bacteria , also it can balance the DNA gyrase and topoisomerase IV activity, slow the development of resistance. Topical administration can achieve stable and lasting high concentrations in human tears , and penetration in animal ocular tissue is good, showing excellent safety.
Pharmacokinetic and pharmacodynamic characteristics of Besifloxacin meet the criteria for successfully clearing most Gram-positive and Gram-negative bacteria, while exhibiting minimal systemic exposure.Besifloxacin biochemical properties, pharmacokinetics targeted to achieve/pharmacodynamic objectives and limited to local ophthalmic drug will slow the development of bacterial resistance, making Besifloxacin become attractive choice for acute bacterial conjunctivitis treatment.
The above information is edited by the chemicalbook of Tian Ye. ;
Supplier
Nanjing Sincerity Chemical Co. Ltd.
Telephone025-57621892 13245250309
Websitehttp://www.njsincerity.com
Hangzhou Kehui Pharmaceutical Co.,Ltd
Telephone0571-87359773 18094707759
Websitehttp://www.hzkehuipharma.com
HANGZHOU YOUHELIN PHARMTECH CO.LTD
Telephone18268150871; 17302275155
Websitehttp://www.yhlpharmtech.com
Hangzhou LinghepharmTechnology Co.,Ltd.
Telephone+86-18571465433 18571465433
Websitehttp://www.linghepharm.com/
Shandong Kehui Pharmaceutical Co. LTD
Telephone 13276409687
Websitehttp://www.kehuipharm.cn/
Shanghai Boyle Chemical Co., Ltd.
Telephone
Websitehttp://www.boylechem.com
J & K SCIENTIFIC LTD.
Telephone010-82848833 400-666-7788
Websitehttp://www.jkchemical.com
Meryer (Shanghai) Chemical Technology Co., Ltd.
Telephone021-61259108 18621169109
Websitehttps://www.meryer.com/cn/index/
ZHIWE CHEMTECH CO LTD
Telephone021-20221225 13917446399
Websitehttp://www.zhiwe.net
Chembest Research Laboratories Limited
Telephone+86-21-20908456
Websitehttp://www.BioChemBest.com
Nanjing Chemlin Chemical Co., Ltd
Telephone025-83697070
Websitehttp://www.echemlin.cn
Chemsky（shanghai）International Co.,Ltd.
Telephone021-50135380
Websitehttp://www.shchemsky.com
Chemipanda Bio-Tech Co., Ltd.
Telephone+86-571-85224801; 13588483690
Websitehttp://www.chemipanda.com
Nanjing Kaitian Chemical Co., Ltd.
Telephone+86 (25) 5860-8846
Websitehttp://www.kt-chem.com/
Nanjing Vital Chemical Co., Ltd.
TelephonePlease Send Email 18652950785
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList15337/0.htm
Dalian Meilun Biotech Co., Ltd.
Telephone0411-62910999 13889544652
Websitehttp://www.meilune.com/
Nanjing JinruiJiuAn Biotechnology Co., Ltd.
Telephone025-58196018 800028039
Websitehttps://www.chemicalbook.com/ShowSupplierProductsList15703/0.htm
Shanghai T&W Pharmaceutical Co., Ltd.
Telephone+86 21 61551611
Websitehttp://www.trustwe.com
1of4
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine